VALID TRIAL
Both CHIA and your personal trial have the following criteria:
╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╤═════════╕
│ Personal Criteria                                  │ CHIA Criteria                                      │   Score │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╪═════════╡
│ Adult male and female aged 19 to 75 years          │ Adult male and female aged 19 to 75 years          │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Voluntarily consented to participate in the study  │ Voluntarily consented to participate in the study  │     100 │
│ and signed the informed consent form after         │ and signed the informed consent form after         │         │
│ receiving the explanation of the objectives,       │ receiving the explanation of the objectives,       │         │
│ methods and effects of the study                   │ methods and effects of the study                   │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Diagnosed with secondary hypertension or suspected │ Diagnosed with secondary hypertension or suspected │     100 │
│ of secondary hypertension \[e.g., renovascular     │ of secondary hypertension [e.g., renovascular      │         │
│ disease, adrenal medullary and cortical            │ disease, adrenal medullary and cortical            │         │
│ hyperfunction, coarctation of the aorta,           │ hyperfunction, coarctation of the aorta,           │         │
│ hyperaldosteronism, unilateral or bilateral renal  │ hyperaldosteronism, unilateral or bilateral renal  │         │
│ artery stenosis, Cushing's syndrome,               │ artery stenosis, Cushing's syndrome,               │         │
│ pheochromocytoma, polycystic kidney disease,       │ pheochromocytoma, polycystic kidney disease, etc.] │         │
│ etc.\]                                             │                                                    │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Diagnosis of type 1 diabetes mellitus (DM) or      │ Diagnosis of type 1 diabetes mellitus (DM) or      │     100 │
│ uncontrolled DM (patients on insulin therapy or    │ uncontrolled DM (patients on insulin therapy or    │         │
│ with HbA1c \> 9%)                                  │ with HbA1c > 9%)                                   │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Patients with severe cardiac conditions: heart     │ Patients with severe cardiac conditions: heart     │     100 │
│ failure (NYHA Class 3 or 4), history of ischemic   │ failure (NYHA Class 3 or 4), history of ischemic   │         │
│ cardiac disease (unstable angina, myocardial       │ cardiac disease (unstable angina, myocardial       │         │
│ infarction), peripheral vascular diseases,         │ infarction), peripheral vascular diseases,         │         │
│ percutaneous transluminal angioplasty or coronary  │ percutaneous transluminal angioplasty or coronary  │         │
│ artery bypass graft within recent 6 months         │ artery bypass graft within recent 6 months         │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Patients with clinically significant ventricular   │ Patients with clinically significant ventricular   │     100 │
│ tachycardia, atrial fibrillation, atrial flutter   │ tachycardia, atrial fibrillation, atrial flutter   │         │
│ or other clinically significant arrhythmia at the  │ or other clinically significant arrhythmia at the  │         │
│ discretion of the investigator                     │ discretion of the investigator                     │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Patients with hypertrophic occlusive               │ Patients with hypertrophic occlusive               │     100 │
│ myocardiopathy, severe occlusive coronary artery   │ myocardiopathy, severe occlusive coronary artery   │         │
│ disease, aortic stenosis, hemodynamically          │ disease, aortic stenosis, hemodynamically          │         │
│ significant aortic valve or mitral valve stenosis  │ significant aortic valve or mitral valve stenosis  │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ History of cardiogenic shock                       │ History of cardiogenic shock                       │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Presence of severe cerebrovascular disorders       │ Presence of severe cerebrovascular disorders       │     100 │
│ (diagnosis of stroke, cerebral infarction or       │ (diagnosis of stroke, cerebral infarction or       │         │
│ cerebral hemorrhage within recent 6 months)        │ cerebral hemorrhage within recent 6 months)        │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ History or current evidence of wasting, autoimmune │ History or current evidence of wasting, autoimmune │     100 │
│ (such as rheumatoid arthritis and systemic lupus   │ (such as rheumatoid arthritis and systemic lupus   │         │
│ erythematosus) or connective tissue diseases       │ erythematosus) or connective tissue diseases       │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Known diagnosis of moderate or malignant           │ Known diagnosis of moderate or malignant           │     100 │
│ retinopathy (including retinal hemorrhage, visual  │ retinopathy (including retinal hemorrhage, visual  │         │
│ disturbance and retinal microaneurysm within 6     │ disturbance and retinal microaneurysm within 6     │         │
│ months)                                            │ months)                                            │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Patients with surgical or medical intestinal       │ Patients with surgical or medical intestinal       │     100 │
│ diseases or having received surgeries that could   │ diseases or having received surgeries that could   │         │
│ interfere with drug absorption distribution,       │ interfere with drug absorption distribution,       │         │
│ metabolism and elimination                         │ metabolism and elimination                         │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ History of malignancy including leukemia and       │ History of malignancy including leukemia and       │     100 │
│ lymphoma within recent 5 years except for          │ lymphoma within recent 5 years except for          │         │
│ localized basal cell carcinoma of the skin)        │ localized basal cell carcinoma of the skin)        │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Patients with any inflammatory diseases requiring  │ Patients with any inflammatory diseases requiring  │     100 │
│ chronic anti-inflammatory therapy                  │ chronic anti-inflammatory therapy                  │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Renal failure on dialysis                          │ Renal failure on dialysis                          │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Needs for co-administration of non-study           │ Needs for co-administration of non-study           │     100 │
│ antihypertensive agents or contraindicated         │ antihypertensive agents or contraindicated         │         │
│ medications during the study                       │ medications during the study                       │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ History of hypersensitivity to ARBs or             │ History of hypersensitivity to ARBs or             │     100 │
│ dihydropyridines                                   │ dihydropyridines                                   │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ History of angioedema to treatment with ACE        │ History of angioedema to treatment with ACE        │     100 │
│ inhibitors or ARBs                                 │ inhibitors or ARBs                                 │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Pregnant or lactating women and female volunteers  │ Pregnant or lactating women and female volunteers  │     100 │
│ of childbearing potential (except for women who    │ of childbearing potential (except for women who    │         │
│ are surgically sterile) who are not willing to use │ are surgically sterile) who are not willing to use │         │
│ an adequate method of contraception (oral          │ an adequate method of contraception (oral          │         │
│ contraceptives, intrauterine device, condom, etc.) │ contraceptives, intrauterine device, condom, etc.) │         │
│ during the study. Women of childbearing potential  │ during the study. Women of childbearing potential  │         │
│ who are not surgically sterile will be allowed to  │ who are not surgically sterile will be allowed to  │         │
│ participate in the study only if they have         │ participate in the study only if they have         │         │
│ negative pregnancy test at Visit 1 (screening) and │ negative pregnancy test at Visit 1 (screening) and │         │
│ should continue to use medically acceptable method │ should continue to use medically acceptable method │         │
│ of contraception (basic body temperature method    │ of contraception (basic body temperature method    │         │
│ and rhythm method will not be allowed). Women with │ and rhythm method will not be allowed). Women with │         │
│ no menses for ≥ 12 months will be considered as    │ no menses for = 12 months will be considered as    │         │
│ postmenopausal state and method of contraception   │ postmenopausal state and method of contraception   │         │
│ using hormonal contraception such as oral          │ using hormonal contraception such as oral          │         │
│ contraceptive should be initiated from or prior to │ contraceptive should be initiated from or prior to │         │
│ the screening                                      │ the screening                                      │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ History of drug or alcohol abuse within recent 1   │ History of drug or alcohol abuse within recent 1   │     100 │
│ year                                               │ year                                               │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Patients having received any other investigational │ Patients having received any other investigational │     100 │
│ product within recent 12 weeks                     │ product within recent 12 weeks                     │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Conditions which render a subject ineligible for   │ Conditions which render a subject ineligible for   │     100 │
│ the study at the discretion of the investigator    │ the study at the discretion of the investigator    │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Blood pressure taken at screening and              │ Blood pressure taken at screening and              │      98 │
│ randomization is ≥ 180 mmHg for siSBP or ≥ 110     │ randomization is = 180 mmHg for siSBP or = 110     │         │
│ mmHg for siDBP                                     │ mmHg for siDBP                                     │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Serum creatinine \> 1.5 x ULN                      │ Serum creatinine > 1.5 x ULN                       │      98 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Serum potassium \< 3.5 mmol/L or \>5.5 mmol/L      │ Serum potassium < 3.5 mmol/L or >5.5 mmol/L        │      98 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ The difference in blood pressure between the       │ The difference in blood pressure between the       │      99 │
│ selected arm versus non-selected arm is ≥ 20 mmHg  │ selected arm versus non-selected arm is = 20 mmHg  │         │
│ for siSBP and ≥ 10 mmHg for siDBP at Visit 1       │ for siSBP and = 10 mmHg for siDBP at Visit 1       │         │
│ (screening)                                        │ (screening)                                        │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Patients with symptomatic orthostatic hypertension │ Patients with symptomatic orthostatic hypertension │      99 │
│ (the difference in the blood pressures between     │ (the difference in the blood pressures between     │         │
│ measured at supine position and measured at        │ measured at supine position and measured at        │         │
│ standing position is ≥ 20 mmHg for siSBP and ≥ 10  │ standing position is = 20 mmHg for siSBP and = 10  │         │
│ mmHg for siDBP)                                    │ mmHg for siDBP)                                    │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ AST or ALT \>2 x upper limit of normal (ULN)       │ AST or ALT >2 x upper limit of normal (ULN)        │      99 │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╧═════════╛

Only your personal trial has the following criteria:
╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╤═════════╕
│ Personal Criteria                                  │ CHIA Criteria                                      │   Score │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╪═════════╡
│ Laboratory abnormalities as follows                │ History of cardiogenic shock                       │      38 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Diagnosed with essential hypertension              │ History of drug or alcohol abuse within recent 1   │      42 │
│                                                    │ year                                               │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ 1. Patients with essential hypertension who have   │ The difference in blood pressure between the       │      46 │
│ shown inadequate response (mean siSBP ≥ 140 mmHg   │ selected arm versus non-selected arm is = 20 mmHg  │         │
│ or mean siDBP ≥ 90 mmHg) to treatment with         │ for siSBP and = 10 mmHg for siDBP at Visit 1       │         │
│ amlodipine or candesartan cilexetil                │ (screening)                                        │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Patients with essential hypertension meeting one   │ Patients with any inflammatory diseases requiring  │      48 │
│ of the following two inclusion criteria            │ chronic anti-inflammatory therapy                  │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ 2. Patients with essential hypertension with blood │ Patients with symptomatic orthostatic hypertension │      54 │
│ pressure adequately controlled by co-              │ (the difference in the blood pressures between     │         │
│ administration of amlodipine besylate and          │ measured at supine position and measured at        │         │
│ candesartan cilexetil (mean siSBP \< 140 mmHg and  │ standing position is = 20 mmHg for siSBP and = 10  │         │
│ mean siDBP \< 90 mmHg)                             │ mmHg for siDBP)                                    │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Must have minimum age of 19 Years                  │ Adult male and female aged 19 to 75 years          │      54 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Must have maximum age of 75 Years                  │ Adult male and female aged 19 to 75 years          │      59 │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╧═════════╛

CHIA has no unique criteria

Levenshtein Ratio of Entire trial at once: 93
Average Levenshtein Ratio of individual lines: 89.48571428571428
OverAll Ratio: 91.24285714285713
